Hot Features
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides re... Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.17 | -4.72222222222 | 3.6 | 3.76 | 3.282 | 510667 | 3.41931602 | CS |
| 4 | -0.87 | -20.2325581395 | 4.3 | 4.46 | 3.282 | 594782 | 3.6579674 | CS |
| 12 | -0.33 | -8.77659574468 | 3.76 | 4.46 | 3.282 | 542690 | 3.84889956 | CS |
| 26 | -1 | -22.5733634312 | 4.43 | 5.478 | 3.26 | 613108 | 4.01253249 | CS |
| 52 | -0.11 | -3.10734463277 | 3.54 | 5.55 | 2.83 | 648270 | 3.96150267 | CS |
| 156 | -9.67 | -73.8167938931 | 13.1 | 14.07 | 2.645 | 544483 | 6.09300451 | CS |
| 260 | -1.43 | -29.4238683128 | 4.86 | 14.3398 | 2.46 | 751138 | 5.49057999 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.